Biora Ebit Per Revenue from 2010 to 2024
| BIOR Stock | USD 1.93 0.14 7.82% |
Ebit Per Revenue | First Reported 2010-12-31 | Previous Quarter -16.8 K | Current Value -15.9 K | Quarterly Volatility 5.8 K |
Check Biora Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biora Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 277.2 K, Interest Income of 950.4 K or Depreciation And Amortization of 527.2 K, as well as many indicators such as Price To Sales Ratio of 55.9 K, Dividend Yield of 6.0E-4 or Days Sales Outstanding of 79.5 K. Biora financial statements analysis is a perfect complement when working with Biora Therapeutics Valuation or Volatility modules.
Biora | Ebit Per Revenue |
Latest Biora Therapeutics' Ebit Per Revenue Growth Pattern
Below is the plot of the Ebit Per Revenue of Biora Therapeutics over the last few years. It is Biora Therapeutics' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biora Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ebit Per Revenue | 10 Years Trend |
|
Ebit Per Revenue |
| Timeline |
Biora Ebit Per Revenue Regression Statistics
| Arithmetic Mean | (2,203) | |
| Coefficient Of Variation | (261.17) | |
| Mean Deviation | 3,777 | |
| Median | (0.89) | |
| Standard Deviation | 5,753 | |
| Sample Variance | 33.1M | |
| Range | 16.8K | |
| R-Value | (0.59) | |
| Mean Square Error | 23.1M | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | (763.27) | |
| Total Sum of Squares | 463.3M |
Biora Ebit Per Revenue History
About Biora Therapeutics Financial Statements
Biora Therapeutics shareholders use historical fundamental indicators, such as Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Although Biora Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Biora Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Biora Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Ebit Per Revenue | -16.8 K | -15.9 K |
Pair Trading with Biora Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Biora Stock
| 0.81 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.95 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Biora Stock
| 0.91 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.81 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.62 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.6 | PHVS | Pharvaris BV | PairCorr |
| 0.4 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.
The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.